NCIC CLINICAL TRIALS GROUP

RADIATION FORUM

MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

ROOM: SEYMOUR

FRIDAY, APRIL 26, 2013 - 8:00 AM - 12:00 PM

CHAIR: A. NICHOL ON BEHALF OF M. MCKENZIE

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To understand and address, through clinical and translational research, the disease burden associated with solid tumours and haematological malignancies treated with radiotherapy in Canada.
- To review recent developments in the understanding of molecular biology of cancers treated with radiotherapy.
- To update, review, and discuss recent results of clinical studies involving radiotherapy conducted by the NCIC Clinical Trials Group or national/international collaborators.
- To provide a learning environment supportive to new investigators.
- To understand and apply new clinical trial methodologies in the field of clinical research.

8:00 am	Welcome	A. Nichol	
	NCIC CTG led trials: Ongoing		
8:05 am	Dexamethasone vs. placebo in the prophylaxis of radiation-induced pain flare following palliative radiotherapy for bone met. NCIC CTG SC.23	R. Wong	
	NCIC CTG Intergroup studies: Ongoing		
8:10 am	Radiation doses and fractionation schedules for DCIS of the breast. NCIC CTG MA.33	I. Olivotto	
<u>Updates in NCIC CTG approved studies</u> :			
8:15 am	HDR brachytherapy in intermediate risk CaP. NCIC CTG PR.15	E. Vigneault	
8:30 am	Preoperative Chemoradiotherapy vs. Preoperative Chemotherapy for Resectable Gastric Cancer. NCIC CTG GA.1	J. Ringash / R. Wong	

8:45 am	Radiation vs. Radiation Plus W. Parulo Chemotherapy with Palliative Intent in Locally Advanced or Locally Recurrent Recurrent CTG CO.22	Palliative Intent	
8:50 am	SBRT vs. CRT for complex spinal metastasis. NCIC CTG SC.24	A. Sahgal / R. Wong	
	Updates on previous discussed proposals		
9:05 am	Randomized study of single 8 Gy versus BSC for symptomatic primary or metastatic liver ca		
9:20 am	HDRBT in operable rectal cancer	T. Vuong	
9:35 am	Coffee break		
	New Study proposals		
9:50 am	Stereotactic RT for oligo-progression of metastatic kidney cancer patients on 1 st line targeted therapy: Phase II	P. Cheung	
10:05 am	Comprehensive RT for oligometastatic NSCLO randomized Phase II	C: P. Cheung	
10:20 am	Hypofractionated schedules of conventional for 'complicated' bone metastases	RT K. Dennis	
10:35 am	Phase III regional radiotherapy in early breast cancer treated by breast-conserving surgery and sentinel lymph node biopsy	t I. Kong	
10:50 am	Accelerated Radiotherapy alone in Favorable HPV(+) SCCHN	B. O'Sullivan / J. Waldron	
11:05 am	Induction Chemotherapy followed by Accelerated Radiotherapy Alone in Unfavorable HPV(+) SCCHN	B. O'Sullivan / E. Winquist	
11:20 am	Dosimetric planning feasibility for HPV (-) locally advanced patients who are not candid for chemotherapy	L. Eapen lates	
11:35 am	A randomized phase II study for patients with T4 rectosigmoid cancer	T. Vuong	
12:00 pm	Meeting adjourned		